Drug Trial Radar · NCT04436497
HEALEY ALS Platform Trial - Regimen A Zilucoplan
Last checked: Nov 20, 2026Latest source record: Jul 25, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
162
Actual
Start
Jul 29, 2020
Primary completion
Apr 13, 2022
Study completion May 4, 2022
Sponsor
- Lead sponsor
- Merit E. Cudkowicz, MDAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Ra Pharmaceuticals
- First posted
- Jun 18, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The HEALEY ALS Platform Trial is a perpetual multi-center, multi-regimen clinical trial evaluating the safety and efficacy of investigational products for the treatment of ALS. Regimen A will evaluate the safety and efficacy of a single study drug, zilucoplan, in participants with ALS.
Conditions
- Amyotrophic Lateral Sclerosis
Interventions
ZilucoplanDrug
Drug: Zilucoplan Administration: Subcutaneous injection Dosage: 0.3mg/kg administered daily
Matching PlaceboDrug
Drug: Matching Placebo Administration: Subcutaneous injection Dosage: Daily subcutaneous injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Disease Progression as Assessed by the ALSFRS-R Total ScoreTime frame: Baseline through 24 Weeks
- Mortality Event RateTime frame: Baseline through 24 Weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Healey Center for ALS at Mass General
Boston, Massachusetts
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.